This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Multiple sclerosis
  • /
  • Alemtuzumab for the treatment of multiple sclerosi...

Alemtuzumab for the treatment of multiple sclerosis

Read time: 1 mins
Published:1st Mar 2018
Author: Evan JR, Bozkurt SB, Thomas NC, Bagnato F.
Availability: Pay for access, or by subscription
Ref.:Expert Opin Biol Ther. 2018;18(3):323-334.
Alemtuzumab for the treatment of multiple sclerosis

Alemtuzumab is a monoclonal antibody that targets for the destruction CD52+ cells, particularly B and T cells. Alemtuzumab is approved in more than 50 countries around the world for the treatment of adult patients with relapsing remitting multiple sclerosis (MS).

Areas covered: In this review, the authors summarize biological, clinical and safety data related to the use of alemtuzumab in patients with MS. The authors then provide their expert opinion on alemtuzumab and the field as of whole before providing their perspectives for the future.

Expert opinion: Alemtuzumab is highly efficacious; more so than first line treatments but comparable to natalizumab. Treatment schedule makes alemtuzumab administration easy and attractive to patients. However, its safety profile makes it a choice for a very limited number of patients, in a specific disease window. As of now, a cure for MS remains elusive and there is an unmet need for a safe and highly potent agent at the level of and beyond the blood brain barrier.

Read abstract on library site  Access full article